Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

KyungAh Im

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Journal of the American Heart Association|January 13, 2017
Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) TrialAlon Eisen, Christopher P Cannon, Eugene Braunwald, et al.
Clinical Chemistry|April 17, 2019
Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
The American Journal of Medicine|November 3, 2015
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1cMatthew A Cavender, Benjamin M Scirica, Itamar Raz, et al.
JAMA Cardiology|September 30, 2016
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical TrialBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|May 26, 2016
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 TrialAvivit Cahn, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care|November 1, 2016
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Gil Leibowitz, Deepak L Bhatt, et al.
Journal of the American College of Cardiology|June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialDavid M Charytan, Marc S Sabatine, Terje R Pedersen, et al.
NEJM Evidence|December 24, 2024
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with EvolocumabAndré Zimerman, Michelle L O'Donoghue, Xinhui Ran, et al.
Circulation. Arrhythmia and Electrophysiology|January 27, 2016
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) TrialAn H Bui, Christopher P Cannon, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology|December 24, 2019
Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary SyndromesAmy A Sarma, Eugene Braunwald, Christopher P Cannon, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Journal of the American Heart Association|January 13, 2017
Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) TrialAlon Eisen, Christopher P Cannon, Eugene Braunwald, et al.
Clinical Chemistry|April 17, 2019
Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
The American Journal of Medicine|November 3, 2015
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1cMatthew A Cavender, Benjamin M Scirica, Itamar Raz, et al.
JAMA Cardiology|September 30, 2016
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical TrialBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|May 26, 2016
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 TrialAvivit Cahn, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care|November 1, 2016
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Gil Leibowitz, Deepak L Bhatt, et al.
Journal of the American College of Cardiology|June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialDavid M Charytan, Marc S Sabatine, Terje R Pedersen, et al.
NEJM Evidence|December 24, 2024
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with EvolocumabAndré Zimerman, Michelle L O'Donoghue, Xinhui Ran, et al.
Circulation. Arrhythmia and Electrophysiology|January 27, 2016
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) TrialAn H Bui, Christopher P Cannon, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology|December 24, 2019
Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary SyndromesAmy A Sarma, Eugene Braunwald, Christopher P Cannon, et al.
Pageof 8